Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome

Gynecological Endocrinology

Volumn 24, Issue 7, 2008, Pages 392-398

  Wu, Jie ^a,b   Zhu, Yiqing ^c   Jiang, Yunfei ^a   Cao, Yaoping ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Hyperandrogenism; Hyperinsulinemia; Metformin; Oral contraceptive pill; Polycystic ovary syndrome

Indexed keywords

DIANE; FOLLITROPIN; LUTEINIZING HORMONE; METFORMIN; TESTOSTERONE;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLITROPIN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; LABORATORY TEST; LOW DRUG DOSE; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; OBESITY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; SCORING SYSTEM; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME; WAIST HIP RATIO;

ADULT; CONTRACEPTIVES, ORAL, COMBINED; CYPROTERONE ACETATE; DRUG THERAPY, COMBINATION; ETHINYL ESTRADIOL; FASTING; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; HYPERANDROGENISM; INSULIN; LUTEINIZING HORMONE; METFORMIN; OBESITY; POLYCYSTIC OVARY SYNDROME; PROSPECTIVE STUDIES; TESTOSTERONE; WAIST-HIP RATIO;

EID: 47749106070     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590802217027     Document Type: Article

References (33)

1. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998;83:3078-3082.
2. Diamanti-Kandarakis E, Christakou C. Prevalence, definition and clinical manifestations of polycystic ovary syndrome. Endocrinol Nutr 2006; 53(Suppl 1):25-33.
3. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF. Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006;91:4237-4245.
4. Dunaif A, Thomas A. Current concepts in the polycystic ovary syndrome. Annu Rev Med 2001;52:401-419.
5. Hacihanefioglu B, Seyisoglu H, Karsidag K, Elter K, Aksu F, Yilmaz T, Gurol AO. Influence of insulin resistance on total renin level in normotensive women with polycystic ovary syndrome. Fertil Steril 2000;73:261-265.
6. Moghetti P. Insulin resistance: what is its role in PCOS? Curr Opin Endocrinol Diabetes 2002;9:444-450.
7. Bruni V, Dei M, Pontello V, Vangelisti P. The management of polycystic ovary syndrome. Ann N Y Acad Sci 2003;997:307-321.
8. Cheang KI, Nestler JE. Should insulin-sensitizing drugs be used in the treatment of polycystic ovary syndrome? Reprod Biomed Online 2004;8:440-447.
9. Taylor AE. Insulin-lowering medications in polycystic ovary syndrome. Obstet Gynecol Clin North Am 2000;27:583-595.
10. Costello MF, Shrestha B, Eden J, Johnson NP, Sjoblom P. Metformin versus oral contraceptive pill in polycystic ovary syndrome: a Cochrane review. Hum Reprod 2007;22:1200-1209.
11. Diamanti-Kandarakis E, Baillargeon J-P, Iuorno MJ, Jakubowicz DJ, Nestler JE. A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills. J Clin Endocrinol Metab 2003;88:1927-1932.
12. Kolodziejczyk B, Duleba AJ, Spaczynski RZ, Pawelczyk L. Metformin therapy decreases hyperandrogenism and hyper-insulinemia in women with polycystic ovary syndrome. Fertil Steril 2000;73:1149-1154.
13. Krysiak R, Okopien B, Gdula-Dymek A, Herman ZS. Update on the management of polycystic ovary syndrome. Pharmacol Rep 2006;58:614-625.
14. De Leo V, La Marca A, Petraglia F. Insulin-lowering agents in the management of polycystic ovary syndrome. Endocr Rev 2003;24:633-667.
15. Yilmaz M, Biri A, Karakoc A, Tortuner F, Bingol B, Cakir N, Tiras B, Avvaz G, Arslan M. The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome. J Endocrinol Invest 2005;28:1003-1008.
16. Genazzani AD, Battaglia C, Malavasi B, Strucchi C, Torolani F, Gamba O. Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome. Fertil Steril 2004;81:114-119.
17. Genazzani AD, Lanzoni C, Ricchieri F, Baraldi E, Casarosa E, Jasonni VM. Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia. Gynecol Endocrinol 2007;23:146-152.
18. Costello M, Shrestha B, Eden J, Sjoblom P, Johnson N. Insulin-sensitizing drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database Syst Rev 2007;24:CD005552.
19. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus working group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to PCOS. Hum Reprod 2004;19:41-47.
20. Goodman A. Terminology and differential diagnosis of genital tract bleeding in women. In: Snyder PJ, Utiger RD, editors. Up to date in endocrinology and diabetes. Wellesley (MA):UpToDate, Inc., 1999.
21. Hatch R, Rosenfield RL, Kim MH, Tredway D. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol 1981;140:815-830.
22. Legro RS, Finegood D, Dunaif A. Fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1998;83:2694-2698.
23. Luque-Ramirez M, Alvarez-Blasco F, Botella-Carretero JI, Martinez-Bermejo E, Lasuncion MA, Escobar-Morreale HF. Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome. J Clin Endocrinol Metab 2007;92:2453-2461.
24. Venturoli S, Marescalchi O, Colombo FM, Macrelli S, Ravaioli B, Bagnoli A, Paradisi R, Flamigni C. A prospective randomized trail comparing low dose flutamide, finasteride, ketoconazole, and cyproterone acetate-estrogen regimens in the treatment of hirsutism. J Clin Endocrinol Metab 1999;84:1304-1310.
25. Iensen JT, Speroff L. Health benefits of oral contraceptives. Obstet Gynecol Clin North Am 2000;27:705-721.
26. Elter K, Imir G, Durmusoglu F. Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovary syndrome: a randomized controlled study. Hum Reprod 2002;17:1729-1737.
27. Cibula D, Sindelka G, Hill M, Fanta M, Skrha J, Zivny J. Insulin sensitivity in non-obese women with polycystic ovary syndrome during treatment with oral contraceptives containing low-androgenic progestin. Hum Reprod 2002;17:76-82.
28. Dunaif A. Insulin resistance and polycystic ovary syndrome: mechanism and implication for pathogenesis. Endocr Rev 1997;18:774-800.
29. Aruna J, Mittal S, Kumar S, Misra R, Dadhwal V, Vimala N. Metformin therapy in women with polycystic ovary syndrome. Int J Gynaecol Obstet 2004;87:237-241.
30. Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia and systolic blood pressure while facilitating normal menses and pregnancy. Metab Clin Exp 1994;43:647-654.
31. Kazerooni T, Dehghan-Kooshkghazi M. Effects of metformin therapy on hyperandrogenism in women with polycystic ovary syndrome. Gynecol Endocrinol 2003;17:51-56.
32. Morin-Papunen L, Vauhkonen I, Koivunene R, Ruokonen A, Martikainen H, Tapanainen JS. Metformin versus ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab 2003;88:148-156.
33. Krstevska B, Dimitrovski Ch, Pemovska G, Misevska S, Dimova Z, Simeonova S, Ahmeti I. Metformin improves menstrual patterns, endocrine and metabolic profile in obese hyperinsulinemic women with a polycystic ovary syndrome. Prilozi 2006;27:57-66.